Changchun Hi-Tech announced on October 13 that Changchun Jinsai Pharmaceutical Co., Ltd., a holding subsidiary of the company, has received the “Notice of Acceptance” approved and issued by the State Drug Administration, and that the application for registration of domestically produced drugs for GenSci 161 injection has been accepted. GenScI 161 injection is a therapeutic biological product class 1 drug independently developed by Jinsai Pharmaceutical. It is a novel all-human monoclonal IgG1 bispecific antibody and is intended for the treatment of recurrent pericarditis.

Changchun Hi-Tech announced on October 13 that Changchun Jinsai Pharmaceutical Co., Ltd., a holding subsidiary of the company, has received the “Notice of Acceptance” approved and issued by the State Drug Administration, and that the application for registration of domestically produced drugs for GenSci 161 injection has been accepted. GenScI 161 injection is a therapeutic biological product class 1 drug independently developed by Jinsai Pharmaceutical. It is a novel all-human monoclonal IgG1 bispecific antibody and is intended for the treatment of recurrent pericarditis.